An inhibitor of VEGF receptor tyrosine kinases
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cediranib

Item No. 11495

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-quinazoline
CAS Number
288383-20-0
Synonyms
  • AZD 2171
  • ZD 2171
Molecular Formula
C25H27FN4O3
Formula Weight
450.5
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS (pH 7.2) (1:20): 0.04 mg/mlEthanol: 3 mg/ml
λmax
235, 320 nm
SMILES
COC(C(OCCCN1CCCC1)=C2)=CC3=C2N=CN=C3OC4=C(F)C(C=C(C)N5)=C5C=C4
InChi Code
InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
InChi Key
XXJWYDDUDKYVKI-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $98

    Add

    10 mg

    $157

    Add

    25 mg

    $318

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Cediranib is a potent inhibitor of VEGF receptor tyrosine kinases, including VEGFR1, 2, and 3 (IC50s = 5, 1, and 3 nM, respectively).1 It also potently inhibits a variety of other receptor and non-receptor tyrosine kinases, including several in the platelet-derived growth factor, fibroblast growth factor, and endothelial growth factor receptor families.1,2 Cediranib blocks tubule formation by human umbilical vein endothelial cells in vitro and prevents angiogenesis as well as xenograft tumor growth in vivo.1 Because of these effects, cediranib has potential use in a range of cancers.3,4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Wedge, S.R., Kendrew, J., Hennequin, L.F., et al. AZD2171: A highly potent, orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65(10), 4389-4400 (2005).

    2. Davis, M.I., Hunt, J.P., Herrgard, S., et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29(11), 1046-1051 (2011).

    3. Bhargava, P., and Robinson, M.O. Development of second-generation VEGFR tyrosine kinase inhibitors: Current status. Curr. Oncol. Rep. 13(2), 103-111 (2011).

    4. Conti, A., Santoni, M., Amantini, C., et al. Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Res. Int. 2013, 419176 (2013).

    5. Castelli, C., Tazzari, M., Negri, T., et al. Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma. J. Transl. Med. 11(1), 237 (2013).